Q0239 Injection, bamlanivimab-xxxx, 700 mg

Short descriptor: Bamlanivimab-xxxx

⚠ Terminated HCPCS Level II 2026
Terminated Code
Q0239 was terminated as of 2021-04-16 and should not be reported for dates of service after that date. This page is retained for historical reference.
Open Q0239 in the app →

Look up Q0239 alongside ICD-10-CM diagnoses, the HCPCS Table of Drugs, and the AI coding assistant.

Q0239 is the HCPCS Level II code for Injection, bamlanivimab-xxxx, 700 mg (2026). It belongs to Section Q — Temporary Codes. Under Medicare, its coverage status is: Carrier judgment. Part B pricing methodology: Vaccinations.

Classification & CMS Attributes

Medicare Coverage
Carrier judgment (code C)
Part B Pricing
Vaccinations (indicator 54)
Type of Service
Pneumococcal/flu/hepatitis B vaccine
Effective Date
2021-04-17
Termination Date
2021-04-16
2026 Maintenance
No change this year

References

Cite This Page

Reference Q0239 with the canonical source and edition:

Q0239 — Injection, bamlanivimab-xxxx, 700 mg. ICD-10 Coding Pro (HCPCS Level II 2026). https://icd10codingpro.com/hcpcs-codes/Q0239

Canonical URL: https://icd10codingpro.com/hcpcs-codes/Q0239

Related Codes in Section Q

← Q0237 Inj, tocilizumab-anoh, hospi Q0240 → Casirivi and imdevi 600 mg
Q0222 Bebtelovimab 175 mg Q0224 Inj, pemivibart, 4500 mg Q0235 Inj, monoclon antibody, 1 mg Q0237 Inj, tocilizumab-anoh, hospi Q0240 Casirivi and imdevi 600 mg Q0243 Casirivimab and imdevimab Q0244 Casirivi and imdevi 1200 mg Q0245 Bamlanivimab and etesevima Q0247 Sotrovimab Q0249 Tocilizumab for covid-19
Browse all HCPCS Level II sections →
Reviewed by Prajwal Shrestha, CPC, CRC
Certified Professional Coder (CPC) and Certified Risk Adjustment Coder (CRC) · AAPC Member ID 01997614 · About · Editorial policy · Content last reviewed: 2026-01-01

Get HCC Mappings, Clinical Summaries, and More

Access premium features including HCC risk adjustment, FDA drug indications, AI coding assistant, and comprehensive clinical context.

Start Free Trial